BCAT-IN-4 Secrets
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Major demo objectives have been to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyosit